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Abstract
Background: Tanzania is currently scaling-up access to anti-retro viral therapy (ART) to reach as
many eligible persons as possible. Hepatitis viral co-infections are known to influence progression,
management as well as outcome of HIV infection. However, information is scarce regarding the
prevalence and predictors of viral hepatitis co-infection among HIV-infected individuals presenting
at the HIV care and treatment clinics in the country.
Methods: A cross-sectional study conducted between April and September 2006 enrolled 260
HIV-1 infected, HAART naïve patients aged ≥18 years presenting at the HIV care and treatment
clinic (CTC) of the Muhimbili National Hospital (MNH). The evaluation included clinical assessment
and determination of CD4+ T-lymphocyte count, serum transaminases and serology for Hepatitis
A, B and C markers by ELISA.
Results: The prevalence of anti HAV IgM, HBsAg, anti-HBc IgM and anti-HCV IgG antibodies were
3.1%, 17.3%, 2.3% and 18.1%, respectively. Dual co-infection with HBV and HCV occurred in 10
individuals (3.9%), while that of HAV and HBV was detected in two subjects (0.8%). None of the
patients had all the three hepatitis viruses. Most patients (81.1%) with hepatitis co-infection neither
had specific clinical features nor raised serum transaminases. History of blood transfusion and
jaundice were independent predictors for HBsAg and anti-HBc IgM positivity, respectively.
Conclusion: There is high prevalence of markers for hepatitis B and C infections among HIV
infected patients seeking care and treatment at MNH. Clinical features and a raise in serum alanine
aminotransferase were of limited predictive values for the viral co-infections. Efforts to scale up
HAART should also address co-infections with Hepatitis B and C viruses.
Background
The National HIV/AIDS Care and Treatment Plan (NCTP)
for Tanzania Mainland launched in 2004 was charged
with the responsibility of providing quality human
immunodeficiency virus (HIV) care and treatment serv-
ices to as many HIV-infected residents of the United
Republic of Tanzania as possible. The operational plan
was to provide antiretroviral treatment to as many
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440,000 AIDS patients by the end of 2008; and to track
the disease progression in some 1.2 million HIV-infected
persons who were not clinically eligible for ART. The plan
recommends that treatment be available through care and
treatment clinics (CTC's) established over a five years
time, at virtually all public and non-public hospitals
down to the district level [1]. By December 2007, the
numbers of health facilities providing HIV care and treat-
ment was 210. These provided non-ART care to estimated
118,286 clients and ART to 69,250 eligible patients [2].
Despite these achievements, relatively little is known
regarding hepatitis viral co-infections among HIV infected
patients enrolling at the CTC's. To the best of our knowl-
edge, this is the first study to determine the prevalence and
predictors of viral hepatitis co-infection among adults
infected with HIV attending a CTC in Tanzania. Thus,
findings obtained will provide valuable information for
stakeholders within and outside Tanzania involved in
scaling up care and treatment services.
Methods
Study design and setting
This was a hospital based descriptive cross-sectional study
conducted at the Muhimbili National Hospital's (MNH)
HIV care and treatment centre (CTC) between April 2006
and September 2006. MNH is a public and tertiary hospi-
tal located in Dar es Salaam, the largest commercial city of
Tanzania.
Study population
Participants were the recently diagnosed HIV infected
patients who were antiretroviral therapy (ART)-naïve,
referred to the MNH-CTC from the various voluntary
counselling and testing (VCT) centres in Dar es Salaam as
well as the medical wards of MNH for initial work-up and
possible initiation of treatment with antiretroviral therapy
(ART).
Interviews and clinical examination
Interviews were conducted using a structured standard
questionnaire to obtain information regarding demo-
graphic characteristics, history of jaundice, and symptoms
of flu-like illness such as fever, nausea and vomiting; dura-
tion of illness, past medical history of blood transfusion,
traditional uvulectomy, scarification, use of parenteral
illicit/recreational drugs, as well as sexual, family and
social histories. Clinical examination, conducted accord-
ing to standard clinical examination methods [3], and the
subsequent staging of patients using the WHO HIV stag-
ing criteria [4], followed the interviews.
Laboratory investigations
Specimens
Blood was collected aseptically into 10 ml vacutainer
tubes (BD, NJ USA) for biochemical, CD4+ count and
viral serology tests. Biochemical and CD4+ T lymphocyte
assays were performed within three hours of collection,
while serum for serological assays of hepatitis A, B and C
markers was stored at -20°C until the time for assay.
CD4+ T-Lymphocytes enumeration
This was determined by flow cytometry using Becton
Dickson Facs Calibur machine.
Alanine aminotransferase (ALAT) assay
The serum aminotransferase determined was alaninie
aminotransferase (ALAT). The catalytic activity of ALAT
(EC 2.6.1.2) was determined in serum using a COBAS
MIRA chemistry analyzer (GMI, MI, USA) after it was cal-
ibrated.
Detection of anti HAV IgM, HBsAg, anti HbcAb IgM and Total anti 
HCV antibodies
The determination of anti hepatitis A virus antibody (anti
HAV IgM), hepatitis B surface antigen (HBsAg), anti hep-
atitis B core IgM antibody (anti HbcAb-IgM), and anti
hepatitis C virus IgG antibody (anti HCV) was done using
the antibody capture ELISA (Adaltis – EIAgen kit). Sam-
ples that had reactivity to HCV were subjected to second
ELISA (Abbott, USA), third-generation ELISA assay. Sam-
ples were considered to be positive for HCV if were reac-
tive for both ELISAs.
Data handling and statistical analysis
Data was processed and analysed with SPSS version 12.0
[5]. The seroprevalence of HAV, HCV and HBV were
expressed in percentages with their corresponding 95%
CIs. Pearson's Chi-Square (χ2) was used to determine the
association between the independent variables, however,
where the numbers in a cell was less than 5, a Fisher's
exact test was used instead. To approach normality, the
baseline absolute CD4+ cell count data was log-trans-
formed and Students' t-test was used to examine the asso-
ciation between the level of immunosuppression and
presence of HAV, HBV and HCV infections. Multiple
logistic regression was used to determine the independent
predictors for each hepatitis and HIV co-infection. A p-
value ≤ 0.05 was considered to be statistically significant.
Ethical issues
Ethical clearance was obtained from the research and pub-
lications committee of the Muhimbili University of
Health and Allied Sciences (MUHAS). Study participants
provided informed written consent prior to enrolment.
Patients found with hepatitis co-infection were started on
triple ART regimen that included lamivudine, with efa-BMC Public Health 2008, 8:416 http://www.biomedcentral.com/1471-2458/8/416
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virenz replacing nevirapine as a non-nucleoside anti-ret-
roviral drug.
Results
Two hundred and sixty HIV infected patients were
recruited during the study period, of whom 70.0% were
females. Table 1 summarises the characteristics of the
study population. The overall mean age was 37.3 (± 9.5)
years, ranging from 19 to 81 years. Males were signifi-
cantly older, with a mean age of 41.4 years compared to
females whose mean age was 35.6 years, p < 0.0001. The
median CD4+ T-lymphocytes was 202 cells/μl.
The seroprevalence of HAV (anti HAV IgM), HBV(HBsAg),
acute HBV(anti HBcAb) and HCV (anti HCV) were 3.1%,
17.3%, 2.3% and 18.1%, respectively (Table 2). Of the six
patients with acute Hepatitis B infection (anti-HBc IgM
antibody positive), two had occult HBV infection (anti
HBc IgM positive but HBsAg negative), and the remaining
four were positive for HBsAg. HBV carrier state, defined as
being HBsAg positive and HBc IgM antibody negative, was
present in 41 patients (15.8%). The prevalence of any of
the four hepatitis markers was found to be 34.6% (Table
2).
Co-infection with both HBV and HCV (HBsAg and HCV
Ab) occurred in 10 individuals (3.9%) while that of HAV
and HBV (anti HAV IgM and HBsAg) occurred in two sub-
jects (0.8%). None of the investigated patients was found
to be co-infected with HAV and HCV. Similarly, none of
the patients had all the three hepatitis viruses (HAV, HBV
and HCV), (Table 2). There was neither an association
between the occurrence of HBV and HCV nor between
HAV and HBV.
The prevalence of HCV infection increased with age (χtrend
= 4; p = 0.04), with the oldest age group (50+ years) hav-
ing the highest proportion (Table 3). The prevalence of
HBV infection among males (21.8%) was non-signifi-
cantly higher than that among females (15.4%). Simi-
larly, widowed and divorced subjects had the highest
prevalence (39.7%) for HCV while currently married had
the lowest prevalence of HCV (13.8%). Subjects who were
never married had the highest prevalence (20.9%) of HBV
infection. However, there was no statistically significant
association between viral hepatitis infection and sex, mar-
ital status or education status (table 3). Furthermore, uni-
variate analysis showed no association between the
presence of any of the hepatitis viruses with blood trans-
Table 1: Socio-demographic characteristics of the study population (n = 260)
Characteristic Male (%)






Age group < 0.01
18 – 29 3 (3.8) 48 (26.3) 51 (19.6)
30 – 39 38 (48.7) 87 (47.8) 125 (48.1)
40 – 49 28 (35.9) 31 (17.0) 59 (22.7)
50+ 9 (11.5) 16 (8.8) 25 (9.6)
Marital Status 0.04
Single 16 (20.5) 51 (28.0) 67 (25.8)
Married 47 (60.3) 83 (45.6) 130 (50.0)
Divorced 10 (12.8) 18 (9.9) 28 (10.8)
Widowed 5 (6.4) 30 (16.5) 35 (13.5)
Education 0.04
Primary & below 44 (56.4) 125 (68.7) 169 (65.0)
Secondary 22 (28.2) 41 (22.5) 63 (24.2)
Post Secondary 12 (15.4) 16 (8.8) 28 (10.8)
Baseline CD4+ count (cells/μl)
< 200 43 (56.6) 77 (46.1) 120 (49.4)
200 – 350 19 (25.0) 27 (16.2) 46 (18.9)
> 350 14 (18.4) 63 (37.7) 77 (31.7) < 0.01
WHO-HIV stage 0.66
I 15 (19.2) 45 (24.7) 60 (23.1)
II 20 (25.6) 47 (25.8) 67 (25.8)
III 32 (41.0) 72 (39.6) 104 (40.0)
IV 11 (14.1) 18 (9.9) 29 (11.2)BMC Public Health 2008, 8:416 http://www.biomedcentral.com/1471-2458/8/416
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fusion, illicit drug use, uvulectomy and traditional or cos-
metic scarification.
Table 4 shows that out of all patients with HAV infection
50% had nausea and 37.5% had vomiting. These propor-
tions were significantly higher than corresponding pro-
portions among patients without HAV infection.
Moreover, patients with acute HBV (HBcAb IgM) were
more likely to have jaundice (66.7%), hepatomegaly
(66.7%), raised alanine aminotransferase {ALAT}
(66.7%) or raised total bilirubin (66.7%). However, when
clinical features and biochemical markers were consid-
ered together, only 17 out of 90 (18.9%) patients with any
of the markers for hepatitis had jaundice (by history or
examination), or hepatomegaly or elevated ALAT. Impor-
tantly, only 10.0% of the patients co-infected with hepati-
tis virus A, B or C co-infection had abnormal serum ALAT.
Table 4 also shows that the mean CD4+ T-lymphocyte
counts among patients co-infected with either HAV, or
HBV, or HCV were not significantly different from the
mean values among patients without the corresponding
hepatitis co-infection.
A set of variables was selected to search for predictors of
the viral hepatitis infections including, age, sex, blood
transfusion, scarification, nausea and vomiting, jaundice,
palpable hepatomegaly and the presence of other viral
hepatitis infection. Significant predictors of co-infection
with the respective viral hepatitis are summarised in table
5. Presence of nausea, history of prior blood transfusion,
and presence of jaundice were the independent predictors
of HAV, HBV and acute HBV co-infections respectively.
Discussion
This study reveals a high burden of hepatitis viral co-infec-
tion among HIV infected, ART naïve patients who sought
care at a tertiary public health facility in Tanzania, with
more than a third of the study participants being co-
infected.
Table 2: Sero-prevalence of viral hepatitis markers among the 
study population (n = 260)
Marker No (%)  95% CI
HAV-IgM antibodies 8 (3.1) 1.3 – 6.0
HBsAg 45 (17.3) 12.9 – 22.5
HBc IgM antibodies 6 (2.3) 0.9 – 5.0
HCV Ab 47 (18.1) 13.6 – 23.3
HBsAg & HBc IgM  4 (1.6) 0.4 – 3.9
HBsAg & HCV Ab 10 (3.9) 1.9 – 7.0
Any viral marker 90(34.6) 28.9 – 40.7
Table 3: Sero-prevalence of viral hepatitis markers according to demographic characteristics (n = 260)
Characteristic Number tested Anti HAV-IgM + HBsAg + Anti HCV + Any Hepatitis +
N n (%) n (%) n (%) n (%)
Age
18 – 29 51 1 (2.0) 12 (23.5) 7 (13.7) 16 (31.4)
30 – 39 125 3 (2.4) 16 (12.8) 22 (17.6) 38 (30.4)
40 – 49 59 3 (5.1) 15 (25.4) 9 (15.3) 25 (42.4)
50+ 25 1 (4.0) 2 (8.0) 9 (36.0) 11 (44.0)
P*-value ** 0.06 0.09 0.28
Sex
Male 78 1 (1.3) 17 (21.8) 10 (12.8) 27 (34.6)
Female 182 7 (3.8) 28 (15.4) 37 (20.3) 63 (34.6)
P* value 0.442* 0.211 0.149 1
Education
Primary & Below 169 4 (2.4) 29 (17.2) 35 (20.7) 62 (36.7)
Secondary & Above 91 4 (4.4) 16 (17.6) 12 (13.2) 28 (30.8)
P* value 0.456* 0.932 0.133 0.339
Marital status
Never Married 67 2 (3.0) 14 (20.9) 12 (17.9) 24 (35.8)
Currently Married 130 5 (3.8) 23 (17.7) 18 (13.8) 41 (31.5)
Divorced/Widowed 63 1 (1.6) 8 (12.7) 17 (27.0) 25 (39.7)
P* value ** 0.460 0.084 0.522
1. Key: * = fishers' exact test ** = no test done due to small numbers. "Any hepatitis" = positivity of any of the viral markers tested antibodies
2. P* value compares the proportion on each marker by various sociodemographic categoriesBMC Public Health 2008, 8:416 http://www.biomedcentral.com/1471-2458/8/416
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HCV was the most prevalent infection (18.1%) which is in
keeping with the findings of Telatela et al [6] who docu-
mented HCV sero-prevalence of 13.8% among HIV
infected children in the same institution [6]. This preva-
lence is higher than that reported among among blood
donors at the same hospital [7-9] probably due to the fact
that all our subjects were HIV-infected and that HCV has
similar transmission modes as HIV. The lower prevalence
of HCV reported by Wadell et al. [8] could also be due to
the fact that they used an HCV RNA assay, which is a more
stringent assay [10]. The increase in the prevalence of HCV
infection with age that was observed is a reflection of a
cumulative risk with time [11].
We found a higher prevalence of HBsAg (17.3%) com-
pared to a study conducted among blood donors (8.8%–
11.0%) at the same setting [7,9]. Three main reasons are
postulated; firstly, the shared modes of transmission
between HIV and HBV [12]. Secondly, is the known phe-
nomenon of reactivation of HBV in the setting of HIV
immunodeficiency [13] and lastly, the higher rates of
childhood horizontal HBV transmission in sub-Saharan
Africa [14]. It is important to note two subjects with anti
HBc IgM antibodies but negative HBsAg who may have
had occult HBV viremia as demonstrated previously in
HIV subjects [15]. Notably occult HBV infection is likely
to be missed diagnosis when HBsAg is employed as a rou-
tine screening test, which may consequently lead to silent
liver damage.
The prevalence of HAV-IgM (3.1%) reported in this study
is much lower than that of 41.0% found in a Kenyan study
[16]. The difference is most probably due to the fact that
the latter study investigated patients who already had clin-
ical hepatitis as evidenced by jaundice.
About 4% of our study population had dual HBV/HCV
infection evidenced by co-existence of HBsAg and anti-
HCV total antibodies. However, the occurrence of the two
viruses (HBV and HCV) was not significantly associated,
corroborating the findings of previous studies done in the
country [6,7].
In this study, the association of hepatitis viral co-infection
with serum alanine aminotransferase (ALAT) as well as
clinical features was very limited. Only 10% of HIV/hepa-
titis co-infected patients had elevated ALAT and clinical
features suggestive of acute liver disease were insignifi-
cantly associated with hepatitis co-infection. The asymp-
tomatic pattern of co-infection in our study population
would probably be due to the fact that we detected less
subjects with acute hepatitis (HAV-IgM 3.1%, HBsAg
2.3%) compared to those with chronic HBV and HCV co-
infection. The paucity of signs and symptoms of liver
damage has been documented in HIV patients with
chronic viral hepatitis co-infection [17,18] and has been
attributed to decreased hepatocellular injury associated
with the HIV-induced immunodeficiency [19].
In this study, except for the association between age and
HCV infection, demographic characteristics were not asso-
ciated with the occurrence of any of the investigated hep-
atitis infections. Our results show that HCV co-infection
Table 4: Clinical characteristics of patients with viral hepatitis markers (n = 260)
HAV-IgM +ve HbsAg +ve HBcIgM +ve HCV-ab +ve
Clinical feature, n (%)
Fever 3 (37.5) 17 (37.8) 2 (33.3) 18 (38.3)
Nausea 4 (50.0)* 5 (11.1) 1 (16.7) 7 (14.9)
Vomiting 3 (37.5)* 6 (13.3) 1 (16.7) 4 (8.5)
Jaundice 0 5 (11.1) 4 (66.7)* 4 (8.5)
Hepatomegaly 0 5 (11.1) 4 (66.7)* 3 (6.4)
Biochemical characteristics, n (%)
Elevated ALAT 1 (12.5) 4 (8.9) 2 (33.3)* 2 (4.3)
Elevated Total bilirubin 0 5 (11.1) 4 (66.7)* 5 (10.6)
Immunological characteristic
Mean CD4+ T-cells (cells/μl) 113 198 134 222
* = P < 0.05, when compared with those having no corresponding marker
Table 5: Likelihood of viral hepatitis co-infection using clinical 
features presented as odds ratios (OR) with 95% confidence 
intervals (CI) (n = 243)*
Outcome Predictor OR (95% CI) p-value
HAV Nausea 4.18 (1.46 – 11.96) < 0.01
HBsAg Blood transfusion 2.59 (1.09 – 6.15) 0.03
HBcAb Jaundice 41.07 (6.78 – 248.89) < 0.01
*CD 4+ T lymphocyte counts for 17 patients were lost and could not 
be traced.BMC Public Health 2008, 8:416 http://www.biomedcentral.com/1471-2458/8/416
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was associated with increasing age, which may reflect a
cumulative risk over time as previously reported by
Kondili [11]. Notably, we observed no statistically signif-
icant association between the occurrence of the either
HBsAg or HCV and sex and marital status, which is in
keeping with other studies conducted in the country [20].
In this study there was no association between absolute
CD4+ T-lymphocyte count and the presence of hepatitis
co-infection. Indeed the association between hepatitis
viral co-infection and CD4+ T lymphocytes count is cur-
rently a subject of debate, with some studies showing no
existence of a relationship [21] and others showing the
association [22]. The lack of association is probably due to
the impaired qualitative response to hepatitis virus in HIV
infection rather than impairment in the absolute numbers
of CD4+ T-lymphocytes [23]. However, the lack of associ-
ation in our study could also be due to that fact that most
of our study patients had low CD4 counts, (median < 202
cells/mm3) at baseline.
Evidently from this study is the fact that most (> 80%) of
the patients with hepatitis viral co-infection, presented
with no specific liver damage-related signs and biochemi-
cal changes, emphasizing the need for routine screening
of viral markers in HIV patients. This is currently not part
of the Tanzanian HIV care and treatment guidelines [24].
Secondly, there are implications for the choice of an
appropriate regimen for the hepatitis co-infected patients
that should include two active anti HBV agents to avoid
viral mutations and thus enhance outcome [25,26]. The,
current first line ART regimen in Tanzania (stavudine,
lamivudine and nevirapine or efavirenz) [24] does not
sufficiently cover for HBV [25]. Moreover, a prolonged use
lamivudine against HIV infection in undiagnosed viral
hepatitis infection may result in resistant HBV mutants
[27]. Flexibility in the regimen under such circumstances
to include appropriate drugs to take care of HBV or HCV
co-infections should be considered. In addition, it is likely
that the undiagnosed cases of hepatitis co-infected
patients may be kept on nevirapine based ART combina-
tions leading to nevirapine hepatotoxicity [28], and thus
defeating the national objective of improving the quality
of life of these patients [24]. Finally, patients with HIV/
Hepatitis co-infection may complicate ART with an
immune reconstitution syndrome (IRIS), which may be
confused with drug toxicity or acute hepatitis infection. It
is therefore important for health care workers to be cogni-
sant of these facts to improve the care of patients infected
with HIV
Conclusion
HBV and HCV infections are relatively common among
Tanzanian HIV patients and should be considered during
baseline work-up of HIV patients in order to provide
appropriate ART. The limited predictive value of clinical
features and biochemical markers indicate that care and
treatment centers should be equipped with laboratory
facilities to diagnose hepatitis viral co-infection. Scaling
up of ART services in the country should go hand in hand
with reviewing HIV treatment guidelines to cater for HBV/
HCV co-infection.
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